Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949939 | 0.78 | — | — | |
| SCHEMBL356196 | 0.77 | CYP1A2 (0.32) | — | |
| SCHEMBL3730646 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL756845 | 0.76 | CYP1A2 (0.31) | — | |
| SCHEMBL11852482 | 0.73 | TRPA1 (0.48) | TRPA1TRPV1MIF | |
| SCHEMBL5932315 | 0.71 | FDPS (0.31) | — | |
| SCHEMBL8761274 | 0.70 | MIF (0.56) | TRPA1TRPV1MIF | |
| SCHEMBL4460900 | 0.66 | — | — | |
| SCHEMBL4563920 | 0.65 | — | — | |
| SCHEMBL331115 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409995-A1 | SINGLE-MOLECULE PEPTIDE SEQUENCING THROUGH MOLECULAR BARCODING AND EX-SITU ANALYSIS | GLYPHIC BIOTECHNOLOGIES, INC. | 2024-12-12 | — | — | US | claimed |
| CN-111320750-B | Weak acid ionizable amphiphilic zwitterionic carrier, micelle drug delivery system, preparation method and application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | claimed |
| CN-111320750-A | Weak acid ionizable amphiphilic zwitterionic carrier, micelle drug delivery system, preparation method and application thereof | 中国药科大学 | 2020-06-23 | — | — | CN | claimed |
| CN-111320750-B | Weak acid ionizable amphiphilic zwitterionic carrier, micelle drug delivery system, preparation method and application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-111320750-A | Weak acid ionizable amphiphilic zwitterionic carrier, micelle drug delivery system, preparation method and application thereof | 中国药科大学 | 2020-06-23 | — | — | CN | disclosed |
| EP-3452591-A1 | MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING | Encodia, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9968694-B2 | Compositions and methods for non-invasive imaging | MERRIMACK PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| WO-2017192633-A9 | MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING | PROCURE LIFE SCIENCES INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017192633-A1 | MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING | PROCURE LIFE SCIENCES INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170152222-A1 | COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE | THE PROCTER & GAMBLE COMPANY | 2017-06-01 | — | — | US | disclosed |
| US-20170112950-A1 | Compositions and Methods for Non-Invasive Imaging | MERRIMACK PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9511155-B2 | Compositions and methods for non-invasive imaging | MERRIMACK PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150093328-A1 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING | MERRIMACK PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| EP-2838880-A1 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING | Merrimack Pharmaceuticals, Inc. (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013158803-A1 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING | MERRIMACK PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-5124308-A | Reacts with transition metal salt for carbonless paper copying | MINNESOTA MINING AND MANUFACTURING COMPANY | 1992-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152222-A1 | COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE | CRAT, CPT1A, CPT1B | TRPA1 1355/4885TRPV1 3148/4885MIF 647/4885 |
| US-20150093328-A1 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING | MKI67, CA13, FAP | TRPA1 4140/4885TRPV1 4133/4885MIF 2575/4885 |
| US-20170112950-A1 | Compositions and Methods for Non-Invasive Imaging | MKI67, CA13, FAP | TRPA1 4140/4885TRPV1 4133/4885MIF 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.